134 related articles for article (PubMed ID: 11020350)
1. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis.
Hyer ML; Voelkel-Johnson C; Rubinchik S; Dong J; Norris JS
Mol Ther; 2000 Oct; 2(4):348-58. PubMed ID: 11020350
[TBL] [Abstract][Full Text] [Related]
2. Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression.
Hyer ML; Sudarshan S; Schwartz DA; Hannun Y; Dong JY; Norris JS
Cancer Gene Ther; 2003 Apr; 10(4):330-9. PubMed ID: 12679806
[TBL] [Abstract][Full Text] [Related]
3. FasL gene therapy: a new therapeutic modality for head and neck cancer.
ElOjeimy S; McKillop JC; El-Zawahry AM; Holman DH; Liu X; Schwartz DA; Day TA; Dong JY; Norris JS
Cancer Gene Ther; 2006 Aug; 13(8):739-45. PubMed ID: 16543918
[TBL] [Abstract][Full Text] [Related]
4. In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.
Sudarshan S; Holman DH; Hyer ML; Voelkel-Johnson C; Dong JY; Norris JS
Cancer Gene Ther; 2005 Jan; 12(1):12-8. PubMed ID: 15514684
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis.
Hyer ML; Sudarshan S; Kim Y; Reed JC; Dong JY; Schwartz DA; Norris JS
Cancer Biol Ther; 2002; 1(4):401-6. PubMed ID: 12432255
[TBL] [Abstract][Full Text] [Related]
6. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system.
Rubinchik S; Ding R; Qiu AJ; Zhang F; Dong J
Gene Ther; 2000 May; 7(10):875-85. PubMed ID: 10845726
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells.
Hedlund TE; Meech SJ; Srikanth S; Kraft AS; Miller GJ; Schaack JB; Duke RC
Cell Death Differ; 1999 Feb; 6(2):175-82. PubMed ID: 10200564
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
[TBL] [Abstract][Full Text] [Related]
9. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
10. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.
Rubinchik S; Wang D; Yu H; Fan F; Luo M; Norris JS; Dong JY
Mol Ther; 2001 Nov; 4(5):416-26. PubMed ID: 11708878
[TBL] [Abstract][Full Text] [Related]
11. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression.
Chakraborty M; Qiu SG; Vasudevan KM; Rangnekar VM
Cancer Res; 2001 Oct; 61(19):7255-63. PubMed ID: 11585763
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Bertram J; Peacock JW; Tan C; Mui AL; Chung SW; Gleave ME; Dedhar S; Cox ME; Ong CJ
Cancer Res; 2006 May; 66(9):4781-8. PubMed ID: 16651432
[TBL] [Abstract][Full Text] [Related]
13. Fas ligand is constitutively secreted by prostate cancer cells in vitro.
Liu QY; Rubin MA; Omene C; Lederman S; Stein CA
Clin Cancer Res; 1998 Jul; 4(7):1803-11. PubMed ID: 9676859
[TBL] [Abstract][Full Text] [Related]
14. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
Frost P; Ng CP; Belldegrun A; Bonavida B
Cell Immunol; 1997 Aug; 180(1):70-83. PubMed ID: 9316641
[TBL] [Abstract][Full Text] [Related]
15. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY
Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667
[TBL] [Abstract][Full Text] [Related]
16. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.
Hoves S; Krause SW; Halbritter D; Zhang HG; Mountz JD; Schölmerich J; Fleck M
J Immunol; 2003 Jun; 170(11):5406-13. PubMed ID: 12759415
[TBL] [Abstract][Full Text] [Related]
17. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
Li Y; Raffo AJ; Drew L; Mao Y; Tran A; Petrylak DP; Fine RL
Cancer Res; 2003 Apr; 63(7):1527-33. PubMed ID: 12670900
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis.
Costa-Pereira AP; Cotter TG
Br J Cancer; 1999 May; 80(3-4):371-8. PubMed ID: 10408840
[TBL] [Abstract][Full Text] [Related]
19. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
[TBL] [Abstract][Full Text] [Related]
20. Critical roles for JNK, c-Jun, and Fas/FasL-Signaling in vitamin E analog-induced apoptosis in human prostate cancer cells.
Jia L; Yu W; Wang P; Li J; Sanders BG; Kline K
Prostate; 2008 Mar; 68(4):427-41. PubMed ID: 18196534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
